



US company VeriSIM Life acquires start-up Molomics Biotech

- The Catalan start-up Molomics, which specialises in deep tech R&D applied to innovative drug design, has just been acquired by the California-based bioinformatics company VeriSIM Life.
- From its headquarters in the Barcelona Science Park, Molomics advanced the development of a patented technology to design a new generation of therapeutic molecules. The innovation lies in combining Artificial Intelligence (AI) with Human Collective Intelligence (HCI) which allows specialists to detect imperfections in medicines designed solely by AI.
- This is a new success story from the Spanish biotechnology sector derived from an entrepreneurial project developed in the PCB ecosystem. Through this acquisition, for an undisclosed amount, the shareholders will also receive shares in VeriSIM Life, which raised \$15 million (€14.4 million) in a Series A round this January.

Barcelona, 18 May 2022. US company [VeriSIM Life](#), a global benchmark in developing artificial intelligence technology for drug development, has acquired deep tech start-up [Molomics Biotech](#), which holds the patent on technology that integrates human collective intelligence with artificial intelligence, harnessed to design new therapeutic molecules.

Molomics is the latest entrepreneurial success story to come out of the [Barcelona Science Park](#). Created in 2015 by Jascha Blobel (CEO), Giovanni Cincilla (CSO) and Simone Masoni (CTO), most of its capital was in the hands of the founding team, which has guaranteed agile execution of its business plan and maximised profit for investors.

With the transaction, for an undisclosed amount, the vast majority of shareholders will also receive shares in VeriSIM Life, which raised \$15 million (€14.4 million) in a Series A round this January.

From its headquarters in the Barcelona Science Park, Molomics completed development of [patented technology](#) to design new therapeutic molecules. The innovation of this technology lies in integrating human collective intelligence with artificial intelligence to determine in real time new chemical structures with high therapeutic activity and pharmacological properties superior to drugs currently developed or marketed. This combination of machine learning and the knowledge of specialists makes it possible to reduce the number of molecules that are tested unnecessarily, which can represent savings of hundreds of millions of euros for the pharmaceutical industry.

Molomics has used this approach to advance a treatment for Parkinson's disease that addresses levodopa-induced dyskinesia, a movement disorder associated with this disease that can cause significant physical disability in those affected.



Molomics technology complements VeriSIM's BIOiSIM™ artificial intelligence platform to further improve success rates in the discovery, development and approval of new drugs for the most challenging diseases affecting humanity. Combining these two state-of-the-art computational tools will make pre-screening new drugs faster and cheaper, thus increasing the success rate in clinical development.

“This acquisition represents a considerable step forward in our strategy to accelerate our growth over the long term and supplement our proprietary software platform to develop effective patient therapies more rapidly and accurately than traditional methods,” said **Dr Jo Varshney**, founder and CEO of VeriSIM Life. *“Along with advancing research in Parkinson’s Disease, we plan to cover the full spectrum of drug discovery and development to treat neurological, oncological and other life-threatening diseases.”*

“We are excited to join the team at VeriSIM Life and infuse an already powerful translational prediction platform with our unique and highly complementary discovery technology,” said **Dr Jascha Blobel**, CEO of Molomics. *“Our early collaboration has achieved promising initial results, and we believe the best is yet to come.”*

Since it was founded, Molomics has raised more than €1 million in public and private capital. In addition to receiving financial support from the Spanish Ministry of Science and Innovation from the beginning through a Torres Quevedo grant, it has also had support from the [Michael J. Fox Foundation](#) in its projects aimed at Parkinson's disease.

■ About Molomics Biotech

Molomics Biotech (www.molomics.com) is a drug discovery and development company that uses Artificial Intelligence (AI) to create more effective drugs with fewer side effects. The power of its technology lays in combining AI with Human Collective Intelligence (HCI), which allows specialists to detect imperfections in drugs designed by AI. Molomics aims to standardise drug design to enable effective development of new drugs that will allow scientists to come up with the future medicines of humankind.

■ About VeriSIM Life

VeriSIM Life (www.verisimlife.com) has developed a sophisticated computational platform that leverages advanced AI and ML techniques to improve drug discovery and development by greatly reducing the time and money it takes to bring a drug to market. BIOiSIM™ is a first-in-class virtual drug development engine that offers unprecedented value for the drug development industry by narrowing down the number of drug compounds that offer anticipated value for the treatment or cure of specific illnesses or diseases.